Prescribing overview
Convenia is an injectable antibiotic with prolonged persistence; it cannot be withdrawn after administration.
Key prescribing checks
- Do not use in patients with known allergy to cefovecin or beta-lactam antimicrobials. Unlike an oral course, a long-acting injection cannot be withdrawn after it has been administered.
- Obtain appropriate diagnostic and susceptibility information. The label describes organisms against which it is not active, including Pseudomonas and enterococci; a laboratory result must be interpreted clinically.
- Review age, renal status, concurrent protein-bound medications and the full precaution section. Because drug persists for an extended period, plans for adverse-event observation and clinical reassessment matter before injection.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
US veterinary labelSkin infections from susceptible S. intermedius or S. canis
Includes secondary superficial pyoderma, wounds and abscesses.
Use / indication source ↗Cats
US veterinary labelWounds/abscesses from susceptible P. multocida
Not an all-purpose infection indication.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Beta-lactam inhibition of bacterial cell-wall synthesis.
Absorption, distribution, metabolism and elimination
Terminal half-life approximately 133 hours in dogs,166 hours in cats; highly protein-bound, mainly unchanged urinary elimination; persistence up to 65 days.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Convenia
US subcutaneous canine/feline label.
Contraindications · when not to use
- Known cefovecin or beta-lactam allergy; do not repeat after allergic reaction/anaphylaxis.
Precautions & monitoring
- Prolonged clearance may require extended adverse-reaction management. Safety unestablished under four months, in breeding/lactating animals, or via IM/IV routes.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Allergy/anaphylaxis and gastrointestinal illness can occur; prolonged adverse-event management may be necessary.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
| Species & indication | Labeled regimen | Eligibility & source |
|---|---|---|
| DogsLabeled susceptible skin infectionsConvenia 80 mg/mL after reconstitution | 8 mg/kg (3.6 mg/lb) SC · Single injection; veterinarian may give a second for incomplete response Maximum 2 injections | Therapeutic concentrations: S. intermedius 7 days; S. canis 14 days. Safety below 4 months unestablished. Verify full dosing label ↗ |
| CatsLabeled P. multocida skin infectionConvenia 80 mg/mL | 8 mg/kg SC · Single one-time injection Therapeutic concentrations approximately 7 days | Safety below 4 months unestablished. Verify full dosing label ↗ |
No IM/IV substitution.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Convenia
US subcutaneous canine/feline label.
- Protein-binding displacement may increase adverse reactions with highly bound medicines, including carprofen, furosemide, doxycycline and ketoconazole. Subsequent antimicrobial effects remain uncertain; diagnostic-test interference can occur.
Monitoring
Culture first; reassess nonresponse within 3–4 days.
Client counseling
Report illness promptly.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Reconstitute and refrigerate according to label.
Brands, formulations & ingredient identity
Active ingredients
Cefovecin
Other searchable names: Cefovecin sodium
Convenia is supplied as a powder that is reconstituted for subcutaneous injection. Reconstitution, storage and post-mixing validity must follow its actual package instructions.
Cefovecin sodium is the salt name. Do not confuse this medicine with cefpodoxime, cephalexin or another cephalosporin whose name starts similarly.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Convenia
- Formulation
- Reconstituted subcutaneous injection
- Label / product scope
- Dogs · Cats
Long-acting antibiotic with specified US skin-infection indications.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →